Upcoming Journal Club Presentation (37):

Tuesday 22nd November 2022 | 05:30 PM (UK time) | 10:30 AM (MST Edmonton time) | 12:30 PM (EDT NY time) | 09:30 AM (PDT LA time)

Intravenous ketamine for depression: A clinical discussion reconsidering best practices in acute hypertension management
Ryan Yip, Jennifer Swainson, Atul Khullar, Roger S. McIntyre and Kevin Skoblenick.

Front Psychiatry. 2022 Sep 29;13:1017504. doi: 10.3389/fpsyt.2022.1017504. PMID: 36245888; PMCID: PMC9556663.

Presenter:  Kevin Skoblenick, MD, PhD, Department of Emergency Medicine, University of Alberta, Edmonton, AB, Canada; Royal Alexandra Hospital, Edmonton, AB, Canada; Neuroscience and Mental Health Institute, University of Alberta, Edmonton, AB, Canada.

Past Journal Club Presentations (36):

Tuesday 25th October 2022 | 05:30 PM (BST UK time) | 06:30 PM (CEST France time) | 12:30 PM (EDT NY time) | 09:30 AM (PDT LA time)

Evaluation of Early Ketamine Effects on Belief-Updating Biases in Patients With Treatment-Resistant Depression
Hugo Bottemanne, MD; Orphee Morlaas, MS; Anne Claret, MD; Tali Sharot, PhD; Philippe Fossati, MD, PhD; Liane Schmidt, PhD.

JAMA Psychiatry. 2022 Sep 28. doi: 10.1001/jamapsychiatry.2022.2996. Epub ahead of print. PMID: 36169969.

Presenter:  Liane Schmidt, PhD, Control-Interoception Attention Team, Paris Brain Institute, Sorbonne University, National Institute of Health and Medical Research, French National Centre for Scientific Research, Assistance Publique-Hôpitaux de Paris, Hôpital de la Pitié-Salpêtrière, DMU Neuroscience, Paris, France.


Tuesday 11th October 2022 | 05:30 PM (UK time) | 12:30 PM (EDT NY time) | 09:30 AM (PDT LA time)

A Novel, Brief, Fully Automated Intervention to Extend the Antidepressant Effect of a Single Ketamine Infusion: A Randomized Clinical Trial
Rebecca B. Price, Ph.D., Crystal Spotts, M.Ed., Benjamin Panny, B.S., Angela Griffo, B.S., Michelle Degutis, M.S., Nicolas Cruz, M.Ed., Elizabeth Bell, B.S., Kevin Do-Nguyen, B.S., Meredith L. Wallace, Ph.D., Sanjay J. Mathew, M.D., Robert H. Howland, M.D.

Am J Psychiatry. 2022 Sep 21:appiajp20220216. doi: 10.1176/appi.ajp.20220216. Epub ahead of print. PMID: 36128684.

Presenter:  Rebecca B. Price, Ph.D., University of Pittsburgh School of Medicine, Pittsburgh, USA

Tuesday 27th September 2022 | 12.30pm EST | 5.30pm UK

The Pharmacokinetics of Ketamine in the Breast Milk of Lactating Women: Quantification of Ketamine and Metabolites
Philp Wolfson, Rob Cole, Kara Lynch, Cassandra Yun, Jason Wallach, Julane Andries, Melissa Whippo.
J Psychoactive Drugs. 2022 Jul 26:1-5. doi: 10.1080/02791072.2022.2101903. Epub ahead of print. PMID: 35880962.

Presenter: Philp Wolfson, M.D., Psychiatry and Psychotherapy, The Ketamine Research Foundation, CA, USA
Tuesday 13th September 2022 | 12.30pm EST | 5.30pm UK

Ketamine exerts its sustained antidepressant effects via cell-type-specific regulation of Kcnq2
Juan Pablo Lopez, Malte D Lücken, Elena Brivio, Stoyo Karamihalev, Aron Kos, Carlo De Donno, Asaf Benjamin, Huanqing Yang, Alec L W Dick, Rainer Stoffel, Cornelia Flachskamm, Andrea Ressle, Simone Roeh, Rosa-Eva Huettl, Andrea Parl, Carola Eggert, Bozidar Novak, Yu Yan, Karin Yeoh, Maria Holzapfel , Barbara Hauger, Daniela Harbich, Bianca Schmidt, Rossella Di Giaimo, Christoph W Turck, Mathias V Schmidt, Jan M Deussing, Matthias Eder, Julien Dine, Fabian J Theis, Alon Chen.

Neuron. 2022 Jul 20;110(14):2283-2298.e9. doi: 10.1016/j.neuron.2022.05.001. Epub 2022 May 31. PMID: 35649415.

Presenter: Juan Pablo Lopez, PhD, Assistant Professor, Department of Neuroscience Karolinska Institutet, Stockholm, Sweden
Tuesday 26th July 2022 | 12.30pm EST | 5.30pm UK

At-home, sublingual ketamine telehealth is a safe and effective treatment for moderate to severe anxiety and depression: Findings from a large, prospective, open-label effectiveness trial
Thomas D Hull, Matteo Malgaroli, Adam Gazzaley, Teddy J Akiki, Alok Madan, Leonardo Vando, Kristin Arden, Jack Swain, Madeline Klotz, Casey Paleos.
J Affect Disord. 2022 Jul 6;314:59-67. doi: 10.1016/j.jad.2022.07.004. Epub ahead of print. PMID: 35809678.

Presenter: T. Derrick Hull, Ph.D., Institute for Psycholinguistics and Digital Health, United States of America
Tuesday 12th July 2022 | 12.30pm EST | 5.30pm UK

Mapping consent practices for outpatient psychiatric use of ketamine
David S Mathai, Scott M Lee, Victoria Mora, Kelley C O'Donnell, Albert Garcia-Romeu, Eric A Storch.
J Affect Disord. 2022 Sep 1;312:113-121. doi: 10.1016/j.jad.2022.06.036. Epub 2022 Jun 23. PMID: 35753499.

Presenters: David Mathai, M.D., Postdoctoral Researcher and Assistant Faculty, Johns Hopkins Medicine, Baltimore, United States, and Scott Lee, M.D., Psychiatry Resident, Harvard South Shore, Boston, Massachusetts, USA

Tuesday, 28 June 2022  | 10:00pm (UK time)| 5:00pm (NYC time) | Wednesday, 29 June 2022, 6:30am (Adelaide, Australia – South Australia time)

Population pharmacokinetics and pharmacodynamics of the therapeutic and adverse effects of ketamine in patients with treatment-refractory depression
Ahmad Y Abuhelwa, Andrew A Somogyi, Colleen K Loo, Paul Glue, Daniel T Barratt, David J R Foster.
Clin Pharmacol Ther. 2022 May 13. doi: 10.1002/cpt.2640. Epub ahead of print. PMID: 35560226.

Presenter: Prof David J.R. Foster, Ph.D., UniSA: Clinical and Health Sciences, Australian Centre for Precision Health, University of South Australia, Adelaide 5000, South Australia, Australia.


Tuesday 14th June 2022 | 05:30 PM (UK time) | 12:30 PM (EDT NY time) | 09:30 AM (PDT LA time)

Ketamine activates adult-born immature granule neurons to rapidly alleviate depression-like behaviors in mice
Radhika Rawat, Elif Tunc-Ozcan, Tammy L. McGuire, Chian-Yu Peng, and John A. Kessler.
Nat Commun. 2022 May 12;13(1):2650. doi: 10.1038/s41467-022-30386-5. PMID: 35551462; PMCID: PMC9098911.

Presenter: Radhika Rawat, MD/PhD student, Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA


Tuesday 24th May 2022 | 05:30 PM (UK time) | 12:30 PM (EDT NY time) | 09:30 AM (PDT LA time)

Electrophysiological correlates and predictors of the antidepressant response to repeated ketamine infusions in treatment-resistant depression
Sara de la Salle, Jennifer L Phillips, Pierre Blier, Verner Knott.
Prog Neuropsychopharmacol Biol Psychiatry. 2022 Apr 20;115:110507. doi: 10.1016/j.pnpbp.2021.110507. Epub 2021 Dec 28. PMID: 34971723.

Presenter: Sara de la Salle, Ph.D., University of Ottawa Institute of Mental Health Research at the Royal, Ottawa, ON, Canada; School of Psychology, University of Ottawa, Ottawa, ON, Canada.


Tuesday 10th May 2022 | 05:30 PM (UK time) | 12:30 PM (EDT NY time) | 09:30 AM (PDT LA time)

Toward Synergies of Ketamine and Psychotherapy
David S Mathai, Victoria Mora, Albert Garcia-Romeu.
Front Psychol. 2022 Mar 25;13:868103. doi: 10.3389/fpsyg.2022.868103. PMID: 35401323; PMCID: PMC8992793.

Presenter: David Samuel Mathai M.D., Postdoctoral Researcher and Assistant Faculty, Johns Hopkins Medicine, Baltimore, United States


Tuesday 22nd March 2022 | 04:30 PM (UK time) | 12:30 PM (EDT NY time) | 09:30 AM (PDT LA time)

Ketamine Modulates the Neural Correlates of Reward Processing in Unmedicated Patients in Remission From Depression
Vasileia Kotoula, Argyris Stringaris, Nuria Mackes, Ndabezinhle Mazibuko, Peter C T Hawkins, Maura Furey, H Valerie Curran, Mitul A Mehta.
Biol Psychiatry Cogn Neurosci Neuroimaging. 2022 Mar;7(3):285-292. doi: 10.1016/j.bpsc.2021.05.009. Epub 2021 Jun 11. PMID: 34126264.

Presenter:  Vasileia Kotoula, Ph.D., Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, United Kingdom


Tuesday 22nd February 2022 | 5.30 PM (UK time) | 12:30 PM (EDT NY time) | 9.30 AM (PDT LA time)

A Cohort-Based Case Report: The Impact of Ketamine-Assisted Therapy Embedded in a Community of Practice Framework for Healthcare Providers With PTSD and Depression

Shannon Dames, Pamela Kryskow, Crosbie Watler.
Front Psychiatry. 2022 Jan 12;12:803279. doi: 10.3389/fpsyt.2021.803279. PMID: 35095617; PMCID: PMC8790057.

Presenter: Pamela Kryskow, MD, Adjunct Professor - Vancouver Island University; Clinical Instructor - University of BC; Founding Board Member - Canadian Psychedelic Association; Medical Lead - Roots To Thrive (rootstothrive.com); Health and Human Services, Vancouver Island University, Nanaimo, BC, Canada.


Tuesday 25th January 2022 | 5.30 PM (UK time) | 12:30 PM (EDT NY time) | 9.30 AM (PDT LA time)

A retrospective analysis of ketamine intravenous therapy for depression in real-world care settings

L. Alison McInnes, Jimmy J. Qian, Rishab S. Gargeya, Charles DeBattista, Boris D. Heifets.
Journal of Affective Disorders, 2022, , ISSN 0165-0327, https://doi.org/10.1016/j.jad.2021.12.097.

Presenter: L. Alison McInnes, MD, MS, VP, Medical Affairs at Osmind, San Francisco, CA, 94107, USA


Tuesday 11th January 2022 | 5.30 PM (UK time) | 12:30 PM (EDT NY time) | 9.30 AM (PDT LA time)

Cost-utility analysis of esketamine and electroconvulsive therapy in adults with treatment-resistant depression

Kinza Degerlund Maldi, Peter Asellus, Anna Myléus, Fredrik Norström.

BMC Psychiatry. 2021 Dec 7;21(1):610. doi: 10.1186/s12888-021-03601-8. PMID: 34876085.

Presenter:  Kinza Degerlund Maldi, MPH, Department of Epidemiology and Global Health, Umeå University, SE-901 87, Umeå, Sweden


Tuesday 14th December 2021 | 5.30 PM (UK time) | 12:30 PM (EDT NY time) | 9.30 AM (PDT LA time)

Ketamine induces EEG oscillations that may aid anesthetic state but not dissociation monitoring

Shubham Chamadia, Jacob Gitlin, Jennifer Mekonnen, Breanna R Ethridge, Reine Ibala, Katia M Colon, Jason Qu, Oluwaseun Akeju.

Clin Neurophysiol. 2021 Oct 8;132(12):3010-3018. doi: 10.1016/j.clinph.2021.08.021. Epub ahead of print. PMID: 34715426.

Presenter:  Reine-Marcelle Ibala, M.D. Candidate, Class of 2023, Weill Cornell Medical College, New York City, New York, USA.


Tuesday 9th November 2021 | 5.30 PM (UK time) | 12:30 PM (EDT NY time) | 9.30 AM (PDT LA time)

Antianhedonic Effect of Repeated Ketamine Infusions in Patients With Treatment Resistant Depression

Alina Wilkowska, Mariusz Stanisław Wiglusz, Maria Gałuszko-Wegielnik, Adam Włodarczyk and Wiesław Jerzy Cubała.

Front Psychiatry. 2021 Oct 18;12:704330. doi: 10.3389/fpsyt.2021.704330. PMID: 34733182.

Presenter:  Alina Wilkowska, MD, Department of Psychiatry, Faculty of Medicine, Medical University of Gdansk, Gdansk, Poland.


Tuesday 12th October 2021 | 5.30 PM (BST UK time) | 12:30 PM (EDT NY time) | 9.30 AM (PDT LA time)

Age affects temporal response, but not durability, to serial ketamine infusions for treatment refractory depression

Steven Pennybaker, Brian J Roach, Susanna L Fryer, Anusha Badathala, Art W Wallace, Daniel H Mathalon, Tobias F Marton.

Psychopharmacology (Berl). 2021 Aug 7. doi: 10.1007/s00213-021-05939-z. Epub ahead of print. PMID: 34363507.

Presenter:  Tobias F. Marton MD, PhD, Associate Clinical Professor, ECT Service, Department of Psychiatry, Weill Institute for Neurosciences, University of California, San Francisco, USA. 


Tuesday 28th September 2021 | 5.30 PM (BST UK time) | 12:30 PM (EDT NY time) | 9.30 AM (PDT LA time)

Effects of Serial Ketamine Infusions on Corticolimbic Functional Connectivity in Major Depression

Megha M Vasavada, Joana Loureiro, Antoni Kubicki, Ashish Sahib, Benjamin Wade, Gerhard Hellemann, Randall T Espinoza, Eliza Congdon, Katherine L Narr, Amber M Leaver.

Biol Psychiatry Cogn Neurosci Neuroimaging. 2021 Jul;6(7):735-744. doi: 10.1016/j.bpsc.2020.06.015. Epub 2020 Jul 3. PMID: 32900657.

Presenter:  Megha Vasavada, Ph.D., Ahmanson-Lovelace Brain Mapping Center, Department of Neurology, Geffen School of Medicine at the University of California, Los Angeles, CA, USA.


Tuesday 14th September 2021 | 12.30pm EDT | 5.30pm UK

Pilot randomized active-placebo-controlled trial of low-dose ketamine for the treatment of multiple sclerosis-related fatigue

Kathryn C Fitzgerald, Bridget Morris, Aurash Soroosh, Alexandra Balshi, Dermot Maher, Adam Kaplin, Bardia Nourbakhsh.

Mult Scler. 2021 May;27(6):942-953. doi: 10.1177/1352458520936226. Epub 2020 Jul 7. PMID: 32633662; PMCID: PMC7790846.

Presenter: Bardia Nourbakhsh, MD, Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.


Tuesday 27th July 2021 | 12.30pm EDT | 5.30pm UK

Pharmacodynamic interactions between ketamine and psychiatric medications used in the treatment of depression: a systematic review

Jolien Veraart, Sanne Smith-Apeldoorn, Iris Bakker, Berber Visser, Jeanine Kamphuis, Robert Schoevers, Daan J Touw.

Int J Neuropsychopharmacol. 2021 Jun 25:pyab039. doi: 10.1093/ijnp/pyab039. Epub ahead of print. PMID: 34170315.

Presenter: Jolien K.E. Veraart, MD, University of Groningen, University Medical Center Groningen, Department of Psychiatry, Groningen, the Netherlands and PsyQ Haaglanden, Parnassia Psychiatric Institute, The Hague, the Netherlands.

Tuesday 13th July 2021 | 12.30pm EDT | 5.30pm UK

Mystical-type experiences occasioned by ketamine mediate its impact on at-risk drinking: Results from a randomized, controlled trial

Rebecca L Rothberg, Nour Azhari, Nancy A Haug, Elias Dakwar.

 J Psychopharmacol. 2021 Feb;35(2):150-158. doi: 10.1177/0269881120970879. Epub 2020 Dec 13. PMID: 33307947.

Presenter: Elias Dakwar, MD, Associate Professor of Clinical Psychiatry, New York State Psychiatric Institute, Columbia University Medical Center, New York, USA

Tuesday 22nd June 2021 | 12.30pm EDT | 5.30pm UK

A comparison of the pharmacokinetics and NMDAR antagonism-associated neurotoxicity of ketamine, (2R,6R)-hydroxynorketamine and MK-801

Patrick J Morris, Richard D Burke, Alok K Sharma, Daniel C Lynch, Leslie E Lemke-Boutcher, Shiny Mathew, Ikram Elayan, Deepa B Rao, Todd D Gould, Carlos A Zarate Jr, Panos Zanos, Ruin Moaddel, Craig J Thomas. 

Neurotoxicol Teratol. 2021 May 1;87:106993. doi: 10.1016/j.ntt.2021.106993. Epub ahead of print. PMID: 33945878.

Presenter: Patrick Morris, PhD, Division of Preclinical Innovation, National Center for Advancing Translational Sciences, Medical Center Drive Rockville, MD, USA

Tuesday 8th June2021 | 12.30pm EDT | 5.30pm UK

Translating the immediate effects of s-ketamine using hippocampal subfield analysis in healthy subjects-results of a randomized controlled trial

Anna Höflich, Christoph Kraus, Ruth M Pfeiffer, Rene Seiger, Dan Rujescu, Carlos A Zarate Jr, Siegfried Kasper, Dietmar Winkler, Rupert Lanzenberger.

Transl Psychiatry. 2021 Apr 1;11(1):200. doi: 10.1038/s41398-021-01318-6. PMID: 33795646.

Presenter: Anna Höflich, MD, PhD, (tenure track (EV) apl. Prof.), Medical University of Vienna, Department of Psychiatry and Psychotherapy, Neuroimaging Labs, Währinger Gürtel, Vienna, Austria

Tuesday 25th May 2021 | 12.30pm EDT | 5.30pm UK

Effects of Ketamine on Rodent Fear Memory

Kwang H. Choi, Rina Y. Berman, Michael Zhang, Haley F. Spencer and Kennett D. Radford.

Int J Mol Sci. 2020 Sep 28;21(19):7173. doi: 10.3390/ijms21197173. PMID: 32998470.

Presenter: Kwang H. Choi, PhD, Assistant Professor of Psychiatry, Center for the Study of Traumatic Stress, Department of Psychiatry, Uniformed Services University, Bethesda, MD, USA

Tuesday 11th May 2021 | 12.30pm EDT | 5.30pm UK

Ketamine treatment upon memory retrieval reduces fear memory in marmoset monkeys

Philippens IHCHM, Draaisma L, Baarends G, Krugers HJ, Vermetten E. Ketamine treatment upon memory retrieval reduces fear memory in marmoset monkeys. Eur Neuropsychopharmacol. 2021 Apr 26;50:1-11. doi: 10.1016/j.euroneuro.2021.04.004. Epub ahead of print. PMID: 33915317.

Presenter: Ingrid Philippens, Senior Neuroscientist at the Animal science department at Biomedical Primate Research Centre (BPRC), The Hague, South Holland, Netherlands

Tuesday 26th April 2021 | 12.30pm EDT | 5.30pm UK

Midazolam and Ketamine Produce Distinct Neural Changes in Memory, Pain, and Fear Networks during Pain

Vogt KM, Ibinson JW, Smith CT, Citro AT, Norton CM, Karim HT, Popov V, Mahajan A, Aizenstein HJ, Reder LM, Fiez JA. 

Anesthesiology. 2021 Apr 19. doi: 10.1097/ALN.0000000000003774. Epub ahead of print. PMID: 33872345.

Presenter: Keith M. Vogt, MD, PhD, Assistant Professor, Anesthesiology & Perioperative Medicine @ University of Pittsburgh, Department of Anesthesiology, Pittsburgh, PA, USA

Tuesday 13th April 2021 | 12.30pm EDT | 5.30pm UK

Distinct trajectories of antidepressant response to intravenous ketamine

O'Brien B, Lijffijt M, Lee J, Kim YS, Wells A, Murphy N, Ramakrishnan N, Swann AC, Mathew SJ. 

J Affect Disord. 2021 Mar 9;286:320-329. doi: 10.1016/j.jad.2021.03.006. Epub ahead of print. PMID: 33770540.
Presenter: Brittany O'Brien, Ph.D., Assistant Professor, Psychiatry and Behavioral Sciences Baylor College of Medicine Houston, TX, USA

Tuesday 23rd March 2021 | 1.30pm EDT | 5.30pm UK

Single, Fixed-Dose Intranasal Ketamine for Alleviation of Acute Suicidal Ideation. An Emergency Department, Trans-Diagnostic Approach: A Randomized, Double-Blind, Placebo- Controlled, Proof-of-Concept Trial

Domany Y, McCullumsmith CB. 

Arch Suicide Res. 2021 Feb 14:1-16. doi: 10.1080/13811118.2021.1878078. Epub ahead of print. PMID: 33583341
Presenter: Yoav Domany, MD, Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati, Cincinnati, OH, USA; Department of Psychiatry, Sheba Medical Center, Ramat Gan, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel


Tuesday 9th March 2021 | 12.30pm EST | 5.30pm UK

Ketamine Alters Electrophysiological Responses to Emotional Faces in Major Depressive Disorder

Lundin NB, Sepe-Forrest L, Gilbert JR, Carver FW, Furey ML, Zarate CA Jr, Nugent AC. 

J Affect Disord. 2021 Jan 15;279:239-249. doi: 10.1016/j.jad.2020.10.007. Epub 2020 Oct 7. PMID: 33074143

Presenter: Allison C Nugent, Ph.D., Director of the Magnetoencephalography (MEG) Core Facility, National Institute of Mental Health, Bethesda, MD, USA


Tuesday 23rd February 2021 | 12.30pm EST | 5.30pm UK

Comparative effects of (S)-ketamine and racemic (R/S)-ketamine on psychopathology, state of consciousness and neurocognitive performance in healthy volunteers

Torsten Passie, Hans-Anton Adams, Frank Logemann, Simon D Brandt, Birgitt Wiese, Matthias Karst. 

Eur Neuropsychopharmacol. 2021 Jan 21;S0924-977X(21)00007-9 .PMID: 33487513

Presenter: Torsten Passie M.D., Ph.D., Professor of Psychiatry and Psychotherapy Goethe-University Franfurt/Main, Germany; (Visiting Scientist) Hannover Medical School, Germany (affiliate)


Tuesday 9th February 2021 12.30pm EST; 5.30pm UK

Prolonged ketamine infusion modulates limbic connectivity and induces sustained remission of treatment-resistant depression

Siegel JS, Palanca BJA, Ances BM, Kharasch ED, Schweiger JA, Yingling MD, Snyder AZ, Nicol GE, Lenze EJ, Farber NB.  

Psychopharmacology (Berl). 2021 Jan 22. PMID: 33483802.

Presenter: Josh Siegel, MD, PhD, Psychiatry Resident, Washington University St Louis, USA


Tuesday 12th January 2021 12.30pm EST; 5.30pm UK

An RCT of repeated ketamine administration for chronic post-traumatic stress disorder

Feder A, Costi S, Rutter SB, Collins AB, Govindarajulu U, Jha MK, Horn SR, Kautz M, Corniquel M, Collins KA, Bevilacqua L, Glasgow AM, Brallier J, Pietrzak RH, Murrough JW, Charney DS.  

Am J Psychiatry. 2021 Jan 5: doi: 10.1176/appi.ajp.2020.20050596. Epub ahead of print. PMID: 33397139

Presenter: Adriana Feder, Associate Professor, Icahn School of Medicine, Mount Sinai, New York 


Tuesday 10th November 2020 12.30pm EST; 5.30pm UK

Ketamine normalizes subgenual cingulate cortex hyper-activity in depression. 
Morris LS, Costi S, Tan A, Stern ER, Charney DS, Murrough JW. Neuropsychopharmacology (2020), 45(6):975-981.  PMID: 31896116
Presenter: Laurel Morris, Assistant Professor, Icahn School of Medicine, Mount Sinai, New York 

Tuesday 24th November 2020 12:30pm EST; 5.30pm UK

Long-term outcome in outpatients with depression treated with acute and maintenance intravenous ketamine: A retrospective chart review. 
Sakurai H, Jain F, Foster S, Pedrelli P, Mischoulon D, Fava M, Cusin C. J Affect Disord. 2020 Nov 1;276:660-666.
PMID: 32871698
Presenter: Cristina Cusin,  Assistant Professor of Psychiatry, Massachusetts General Hospital


Tuesday 8th December 2020 12:30pm EST; 5.30pm UK

The effectiveness of intravenous ketamine in adults with treatment-resistant major depressive disorder and bipolar disorder presenting with prominent anxiety: Results from the Canadian Rapid Treatment Center of Excellence. 
McIntyre RS, Rodrigues NB, Lipsitz O, Nasri F, Gill H, Lui LM, Subramaniapillai M, Kratiuk K, Teopiz K, Ho R, Lee Y, Mansur RB, Rosenblat JD.  J Psychopharmacol. 2020 Oct 11 Epub ahead of print. 
PMID: 33040665
Presenter: Roger McIntyre,  Professor of Psychiatry and Pharmacology, University of Toronto


Tuesday 22nd December 2020 12:30pm EST; 5.30pm UK

Sex-specific neurobiological actions of prophylactic (R,S)-ketamine, (2R,6R)-hydroxynorketamine, and (2S,6S)-hydroxynorketamine. 
Chen BK, Luna VM, LaGamma CT, Xu X, Deng SX, Suckow RF, Cooper TB, Shah A, Brachman RA, Mendez-David I, David DJ, Gardier AM, Landry DW, Denny CA.  Neuropsychopharmacology. 2020 Aug;45(9):1545-1556. 
PMID: 32417852
Presenter: Christine DennyAssistant Professor of Clinical Neurobiology (in Psychiatry), Columbia University, New York

About Ketamine International Journal Club

  • A series of free, short, 30-minute webinars held every two weeks
  • Held on 2nd and 4th Tuesdays at 12:30pm EST (usually 9:30am Pacific, 5:30pm GMT, 11:00pm Indian Standard)
  • Authors present for 15 minutes followed by 15 minutes answers to written Q&A
  • Recently published papers on ketamine and related compounds for the treatment of psychiatric disorders
  • A balance of RCTs, animal work, experimental medicine / human mechanism, case series
  • Recordings will be made available through the Ketamine Conference website
  • Intended audience: clinicians, clinical and pre-clinical scientists, industry, policy makers
  • Independent of industry funding
  • Programmed and run by academic clinicians at Oxford and psychiatric trainees
  • Complements the Oxford Ketamine Conference
  • Organisers